Balaxi Pharmaceuticals Limited (NSE:BALAXI)
22.85
-0.39 (-1.68%)
Jun 12, 2026, 3:27 PM IST
Balaxi Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 145.59 | 394 | 622.91 | 282.17 | 71.93 |
Short-Term Investments | - | 13.04 | 2.81 | 2.48 | 1.84 |
Cash & Short-Term Investments | 145.59 | 407.03 | 625.72 | 284.65 | 73.77 |
Cash Growth | -64.23% | -34.95% | 119.82% | 285.85% | 342.01% |
Accounts Receivable | 1,361 | 1,108 | 557.05 | 522.82 | 275.59 |
Other Receivables | - | 18.66 | 12.95 | 10.73 | 18.48 |
Receivables | 1,365 | 1,158 | 589.01 | 550.02 | 311.84 |
Inventory | 834.8 | 784.81 | 821.68 | 1,050 | 987.04 |
Prepaid Expenses | - | 22.14 | 20.17 | 37.77 | 31.22 |
Other Current Assets | 168.56 | 55.99 | 45.14 | 12.44 | 6.16 |
Total Current Assets | 2,514 | 2,428 | 2,102 | 1,935 | 1,410 |
Property, Plant & Equipment | 490.11 | 363.11 | 170.87 | 190.16 | 60.27 |
Long-Term Investments | - | - | - | - | 44.7 |
Goodwill | 326.71 | 267.45 | 261 | 252.24 | 233.02 |
Other Long-Term Assets | 39.18 | 45.21 | 49.84 | 19.19 | 16.69 |
Total Assets | 3,370 | 3,103 | 2,583 | 2,397 | 1,765 |
Accounts Payable | 212.08 | 161.78 | 290.38 | 345.19 | 491.15 |
Accrued Expenses | - | 46.02 | 46.1 | 28.02 | 32.6 |
Short-Term Debt | 334.37 | 303.8 | 176.61 | 107.51 | 36.38 |
Current Income Taxes Payable | - | 33.67 | 28.83 | 50.57 | 72.52 |
Other Current Liabilities | 75.13 | 0.05 | 0.05 | 0.05 | 0.03 |
Total Current Liabilities | 621.58 | 545.32 | 541.98 | 531.33 | 632.68 |
Long-Term Debt | 223.53 | 212.45 | - | 8.7 | - |
Long-Term Leases | 18.59 | 18.01 | 17.43 | 16.86 | - |
Long-Term Deferred Tax Liabilities | 13.35 | 9 | 9.95 | 11.01 | 0.39 |
Other Long-Term Liabilities | 2.49 | 1.29 | 0.43 | - | - |
Total Liabilities | 879.53 | 786.06 | 569.79 | 567.89 | 633.06 |
Common Stock | 110.42 | 110.42 | 108.98 | 101.81 | 100 |
Additional Paid-In Capital | - | 565.8 | 508.44 | 192.46 | 112.53 |
Retained Earnings | - | 1,641 | 1,358 | 1,432 | 919.11 |
Comprehensive Income & Other | 2,380 | - | 37.73 | 102.97 | - |
Shareholders' Equity | 2,491 | 2,317 | 2,014 | 1,829 | 1,132 |
Total Liabilities & Equity | 3,370 | 3,103 | 2,583 | 2,397 | 1,765 |
Total Debt | 576.49 | 534.25 | 194.04 | 133.07 | 36.38 |
Net Cash (Debt) | -430.9 | -127.22 | 431.68 | 151.58 | 37.39 |
Net Cash Growth | - | - | 184.78% | 305.40% | - |
Net Cash Per Share | -7.91 | -2.30 | 8.39 | 2.99 | 0.75 |
Filing Date Shares Outstanding | 55.71 | 55.21 | 50.91 | 50.91 | 50 |
Total Common Shares Outstanding | 55.71 | 55.21 | 50.91 | 50.91 | 50 |
Working Capital | 1,893 | 1,882 | 1,560 | 1,404 | 777.36 |
Book Value Per Share | 44.71 | 41.98 | 39.56 | 35.92 | 22.63 |
Tangible Book Value | 2,164 | 2,050 | 1,753 | 1,577 | 898.62 |
Tangible Book Value Per Share | 38.85 | 37.13 | 34.43 | 30.97 | 17.97 |